Y-mAbs Therapeutics Inc. recently delivered a presentation focusing on their Radiopharmaceutical R&D update. The presentation was led by key figures in the company, including Mike Rossi, President and Chief Executive Officer, Natalie Tucker, SVP, Radiopharmaceutical Business Unit Head, and Norman LaFrance, MD, Chief Medical and Development Officer. The company is emphasizing its commitment to advancing radiopharmaceuticals with minimal off-target effects through a fully operational theranostic platform, utilizing proprietary radiohaptens for isotope modularity. The approach aims to disrupt the existing radiopharmaceutical landscape by leveraging existing infrastructure, enhancing patient safety, and increasing physician participation throughout the treatment journey. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.